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Abstract
Background: Recent reports indicate that anaplastic oligodendrogliomas frequently show allelic
losses on chromosome arms 1p and 19q, and that these deletions are associated with better
chemotherapeutic response and overall patient survival. Because of the diversified genetic makeup
of the population and the centralized provincial referral system for brain tumor patients in
Manitoba, the epidemiological features of such tumors sometimes differ from the published data
acquired from non-community based settings. In this study, we assessed the prevalence of allelic
deletions for chromosome arms 1p and 19q in anaplastic and in low-grade oligodendrogliomas in
the Manitoba population.
Methods:  Loss of heterozygosity (LOH) analysis of brain tumors was carried out using 4
microsatellite markers (D1S508, D1S2734, D19S219 and D19S412) and a PCR based assay. The
tumors were consecutively acquired during the period September 1999–March 2001 and a total of
63 tumors were assessed.
Results: We found that allelic loss of chromosome 1p and 19q was higher in oligodendrogliomas
than in other diffuse gliomas and that for anaplastic oligodendrogliomas, younger patients exhibited
significantly more deletions than older patients (>60 years of age).
Conclusions:  These studies suggest that age may be a factor in the genetic alterations of
oligodendrogliomas. In addition, these studies demonstrate that this assay can easily be carried out
in a cost-effective manner in a small tertiary center.
Background
Diffuse gliomas are the most common malignant neo-
plasms of the central nervous system and are comprised of
oligodendrogliomas, astrocytomas, mixed oligoastrocyto-
mas and glioblastomas [1]. Within each subtype there is a
wide spectrum of clinical behavior and response to ther-
apy, yet current strategies to effectively stratify these
lesions by histology are limited to subjective differences in
cellular morphology [2]. Oligodendrogliomas are a major
subtype of gliomas. The anaplastic variant is distinguished
from the others by its remarkable sensitivity and dramatic
response to combination treatment with procarbazine,
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lomustine and vincristine (termed PCV) [3,4]. Anaplastic
oligodendrogliomas further share a constellation of
molecular genetic alterations including coincident loss of
chromosomal arms 1p and 19q in 50–70% of tumors [5].
Furthermore, allelic loss (or loss of heterozygosity, LOH)
of chromosomal arms 1p and 19q was shown to be a sig-
nificant predictor of chemosensitivity and longer recur-
rence-free survival after chemotherapy [5].
Most reports of the prevalence of these changes are
derived from large referral centers such as the Mayo Clinic,
Rochester, Minnesota; the Massachusetts General Hospi-
tal, Boston, Massachusetts; and the University of Bonn
Medical Centre, Bonn, Germany [5-7]. Because of the
apparent value of this information, we wanted to assess
the applicability of the test in a smaller tertiary care center.
We report our initial results following establishment of
this assay at the Health Sciences Centre, Winnipeg, Mani-
toba. In the present study we examined the occurrence of
oligodendrogliomas in this community over an 18-
month period, and whether chromosomal deletions at 1p
and 19q were more frequently associated with these
tumors compared to other gliomas.
Methods
Tissue specimens and histopathology
The referral population in Manitoba is 1.1 million and is
relatively stable. Over an 18-month period, 161 primary
brain tumors were submitted for neuropathological
examination at the Health Sciences Centre, Winnipeg.
This represents roughly the same crude incidence previ-
ously documented in this locale [8]. Among these, 69 glial
neoplasms (comprising mostly of anaplastic oligodendro-
gliomas, low-grade oligodendrogliomas and glioblast-
oma multiforme) were selected for study. This selection
pattern was based on the perceived value of tumor geno-
typing for guiding therapy and the availability of blood.
Thus, tumor subtypes more likely to exhibit 1p and 19q
deletions were selected. This included all tumors histolog-
ically graded as anaplastic oligodendroglioma, oligoden-
droglioma or anaplastic oligoastrocytoma. All tumors
were classified by two neuropathologists and graded
according to the WHO classification system [1,9]. Selected
tumors were placed into 3 major categories (Table 1).
Six of the 69 tumors were recurrent tumors with the same
histopathological grade as the original presenting tumor;
these were excluded from the study. Thus, for statistical
purposes, tumors from the same patient were only consid-
ered once in the study. This study was approved by The
Pathology Access Committee for Tissues (PACT) at the
University of Manitoba.
Tissue sectioning
Twenty 8 µm serial sections were prepared from blocks of
formalin-fixed, paraffin-embedded tissue. Three sections
(slides #1, #10, #20) from each tumor were stained with
hematoxylin and eosin and examined microscopically.
Areas of representative tumor and normal brain tissue
were outlined on the coverglass with permanent marker.
Using slides containing immediately adjacent sections,
regions of tissue corresponding to the outlined areas were
scraped into Eppendorf tubes for DNA extraction. Tissue
sections that were necrotic, calcified or highly vascular
were avoided when possible.
DNA extraction
Tumor DNA was extracted from paraffin sections as previ-
ously described [10]. Briefly, 50–100 µl of proteinase K
buffer solution [10 mM Tris buffer, pH 8.3; 50 mM KCl;
1.5 mM MgCl2; 100 µg/ml bovine serum albumin; 0.45%
Tween 20; 0.45% Nonidet (NP40) and 100 µg/ml protei-
nase K] was added to the scraped tissue and incubated at
55°C for a minimum of 8 hours. Following incubation,
the tubes were heated to 95°C for 10 minutes and cooled
on ice. Tubes were centrifuged to pellet the debris and 1–
2 µl of the supernatant was used in the PCR reaction. Con-
stitutional DNA was extracted from freshly obtained
patient blood leukocytes using DNAzol™ (Invitrogen, Bur-
lington, Ontario) as directed by the manufacturer or
extracted, as above, from paraffin sections of the patient's
non-infiltrated brain tissue.
End-labeling and PCR amplification
Four microsatellite markers (D1S508 and D1S2734, chro-
mosome 1p; D19S219 and D19S412, chromosome 19q)
[5] were used in this study. D1S508 lies proximal to the
centromere and D1S2734 distal on chromosome 1p;
D19S219 lies proximal to the centromere and D19S412
distal on chromosome 19. These microsatellite markers
have been shown to be highly polymorphic and span the
Table 1: Histological subtypes of selected gliomas




Oligodendroglioma samples (Total) 31
Oligodendroglioma, anaplastic 14 3
Oligodendroglioma 17 2
Gliobastoma multiforme 21 4
Other Glioma Samples (Total) 11
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regions of chromosome 1p and 19q that are commonly
lost in anaplastic oligodendrogliomas [5]. The loss of
these markers from each chromosome typically represents
loss of the entire arm in anaplastic oligodendrogliomas
[5]. The primers were synthesized by DNA Laboratories
(University of Calgary, Alberta). All primers were 5' end-
labeled using 32P-γATP (PerkinElmer Life Sciences, Wood-
bridge, Ontario) and T4 polynucleotide kinase (Invitro-
gen, Burlington, Ontario). The reaction was incubated at
37°C for 30 minutes, followed by heat inactivation at
65°C for 15 min. PCR amplification was performed with
32P-labeled primers on a Perkin Elmer 9700 thermocycler.
The reaction consisted of 1 µl of tumor DNA (or 20 ng
normal DNA), 1 pmol of each primer, 0.8 µM dNTP's, 2.5
U Amplitaq Gold DNA polymerase and 1× GeneAmp 10×
PCR Buffer II (PerkinElmer Life Sciences). A hot start was
used to reduce non-specific priming and to minimize any
background bands. The polymerase chain reaction (PCR)
program was as follows: an initial denaturation step of
94°C for 10 min, followed by 30 cycles of: 94°C for 1
min, 60–67°C for 1 min, and 72°C for 1 min, with a final
extension cycle at 72°C for 15 min. The reaction products
were run on a 6% denaturing polyacrylamide-sequencing
gel. A γ32P ATP end-labeled 25-bp ladder (Invitrogen, Bur-
lington, Ontario) was used as a molecular size marker.
The gel was exposed at -70°C overnight.
DNA samples heterozygous for any of the four loci were
considered informative, whereas homozygotes were
deemed "non-informative."
Assay cost
The costs of performing the assay was evaluated by tabu-
lating the cost of all materials used in addition to the cost
of the technologist time, and determining the number of
patient samples that can be analyzed. The depreciation of
all equipment used was not included in the calculations as
this was considered to be minimal.
Statistical Analysis
Fisher's Exact Test was performed with Statistica Software
(StatSoft version 5; Tulsa, Oklahoma) to calculate the P
values for comparison of binomial proportions. The sin-
gle direction of results allowed use of the one-tailed test.
Results
Patients/Glioma Pathology
Table 3 lists the distribution and consensus histologic
subtypes of the gliomas that were analyzed in this study.
The average age of patients at the time of biopsy was 49
years. Sixty eight percent of the patients were male; 32%,
female. The age range of female patients was 2 years to 74
years; for males, 2 years to 78 years. Patients were placed
into 2 general categories for analysis (group1 and 2, Table
1), based on age. Group 1 also included pediatric cases
(2–18 years old, n = 5). Group 2 referred to patients 60
years of age and older (n = 22).
LOH analysis of chromosomes 1 and 19
Figure 1 illustrates representative LOH for each microsat-
ellite marker examined. Table 3 also lists the number of
tumors that were informative and non-informative for
each locus and the breakdown of tumors with or without
deletions. Tumors from 31 patients (49%) had no appar-
ent deletion for either chromosome 1 or 19. Three
patients (5%) showed loss of 1p without loss of 19q, 10
patients (16%) had a loss of 19q without loss of 1p and
19 (30%) had loss of both 1p and 19q. Of the 5 pediatric
patients analyzed, 4 had no deletions. Partial deletions for
chromosome 1p were found in 2 tumors, 1 anaplastic
oligoastrocytoma and 1 glioblastoma multiforme. Both
tumors displayed LOH at the D1S508 locus but not at the
D1S2734 locus (Table 3). Partial deletions were not
observed in the informative oligodendrogliomas.
Correlation between LOH on chromosomes 1p and 19q
A LOH at the D1S2734 locus was always accompanied by
a LOH at the D1S508 locus (Table 3) when informative.
Tumors that exhibited deletions at the D1S2734 locus
also had additional deletions on the long arm of
chromosome19q (D19S412 and D19S219).
Association of 1p and 19q deletions with histological 
subtypes
Oligodendrogliomas accounted for 31/63 of tumors ana-
lyzed and 18/31 of oligodendrogliomas had a 1p and/or
a 19q deletion; 13/18, had both. At the 4 loci examined,
deletions were identified in 8/14 anaplastic oligodendro-
gliomas; 3 had only chromosome 19 deletions whereas 4
Table 2: Primers
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Table 3: Summary of LOH data in 63 gliomas.
Deletion detected
Group Age Sex Chromosome 1 Chromosome 19 Histological Diagnosis: WHO Grade
D1S508 D1S2734 D19S219 D19S412
1 53 F 1 deletion non-informative 0 deletion non-informative oligodendroglioma, anaplastic 3
34 F 1 deletion 1 deletion 1 deletion 1 deletion oligodendroglioma, anaplastic 3
28 F non-informative 0 deletion 0 deletion 0 deletion oligodendroglioma, anaplastic 3
27 M 0 deletion non-informative 1 deletion 1 deletion oligodendroglioma, anaplastic 3
* 16 M 0 deletion 0 deletion 0 deletion non-informative oligodendroglioma, anaplastic 3
48 M non-informative 1 deletion 1 deletion 1 deletion oligodendroglioma, anaplastic 3
45 M 0 deletion 0 deletion 1 deletion 1 deletion oligodendroglioma, anaplastic 3
41 M non-informative 1 deletion 1 deletion 1 deletion oligodendroglioma, anaplastic 3
30 M non-informative 1 deletion 1 deletion non-informative oligodendroglioma, anaplastic 3
57 F non-informative non-informative 1 deletion 1 deletion oligodendroglioma 2
56 M 1 deletion 1 deletion 1 deletion non-informative oligodendroglioma 2
54 F 1 deletion 1 deletion 1 deletion 1 deletion oligodendroglioma 2
53 F 1 deletion 1 deletion 1 deletion 1 deletion oligodendroglioma 2
52 M 1 deletion 1 deletion non-informative 1 deletion oligodendroglioma 2
49 M 1 deletion 1 deletion 1 deletion 1 deletion oligodendroglioma 2
43 F 1 deletion 1 deletion 1 deletion non-informative oligodendroglioma 2
38 F non-informative 0 deletion non-informative 0 deletion oligodendroglioma 2
37 M 1 deletion 1 deletion non-informative 1 deletion oligodendroglioma 2
37 M 0 deletion 0 deletion 0 deletion 0 deletion oligodendroglioma 2
35 M 1 deletion 1 deletion 1 deletion 1 deletion oligodendroglioma 2
32 M non-informative non-informative 0 deletion non-informative oligodendroglioma 2
28 M non-informative 0 deletion non-informative 0 deletion oligodendroglioma 2
25 M 1 deletion non-informative 1 deletion 1 deletion oligodendroglioma 2
* 17 M 0 deletion 0 deletion non-informative 0 deletion oligodendroglioma 2
* 2 F 0 deletion 0 deletion 0 deletion 0 deletion oligodendroglioma 2
#,+ 41 F 1 deletion 0 deletion 1 deletion 0 deletion oligoastrocytoma, anaplastic 3
54 M 0 deletion 0 deletion 0 deletion 0 deletion oligoastrocytoma, anaplastic 3
37 F 0 deletion 0 deletion 1 deletion 1 deletion oligoastrocytoma, anaplastic 3
34 M 0 deletion 0 deletion 0 deletion 0 deletion oligoastrocytoma, anaplastic 3
48 M 0 deletion 0 deletion 0 deletion 0 deletion oligoastrocytoma 2
48 F 0 deletion 0 deletion 0 deletion 0 deletion oligoastrocytoma 2
26 M 1 deletion non-informative 1 deletion 1 deletion oligoastrocytoma 2
59 F 1 deletion non-informative 0 deletion 0 deletion glioblastoma multiforme 4
58 F 0 deletion 0 deletion 1 deletion 1 deletion glioblastoma multiforme 4
57 F non-informative 0 deletion 0 deletion non-informative glioblastoma multiforme 4
53 M 0 deletion 0 deletion 1 deletion 1 deletion glioblastoma multiforme 4
46 F 0 deletion 0 deletion 0 deletion 0 deletion glioblastoma multiforme 4
31 F 1 deletion 1 deletion 1 deletion 1 deletion glioblastoma multiforme 4
29 M 0 deletion 0 deletion 0 deletion non-informative glioblastoma multiforme 4
* 8 M 1 deletion 1 deletion 1 deletion 1 deletion glioblastoma multiforme 4
* 2 M non-informative 0 deletion 0 deletion non-informative glioblastoma multiforme 4
2 62 M 0 deletion 0 deletion non-informative 1 deletion oligodendroglioma, anaplastic 3
70 M non-informative 0 deletion 0 deletion non-informative oligodendroglioma, anaplastic 3
71 F non-informative 0 deletion 0 deletion non-informative oligodendroglioma, anaplastic 3
66 M non-informative 0 deletion 0 deletion non-informative oligodendroglioma, anaplastic 3
74 F non-informative non-informative 0 deletion 0 deletion oligodendroglioma, anaplastic 3
62 M 0 deletion 0 deletion 0 deletion non-informative oligodendroglioma 2
61 M 0 deletion 0 deletion non-informative 0 deletion oligoastrocytoma, anaplastic 3
78 M 0 deletion 0 deletion 0 deletion 0 deletion oligoastrocytoma, anaplastic 3
60 M non-informative 0 deletion 1 deletion 1 deletion glioblastoma multiforme 4
61 M 0 deletion 0 deletion non-informative 0 deletion glioblastoma multiforme 4
64 M 0 deletion non-informative 0 deletion 0 deletion glioblastoma multiforme 4
64 M 0 deletion 0 deletion 0 deletion 0 deletion glioblastoma multiforme 4
# 65 F 1 deletion 0 deletion 1 deletion non-informative glioblastoma multiforme 4BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/6
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displayed both 1p and 19q loss and 1 had only a 1p dele-
tion. In the second largest glioma subtype studied, gliob-
lastoma multiforme, 11/21 had a 1p or a 19q deletion, 4/
11 had a combined 1p and 19q deletion, and 10/21 had
no deletions (Tables 3 and 4; for Table 4, see Additional
file 1).
Correlation between loss of chromosomes 1 and 19 and 
patient age
Of the 63 tumors analyzed, only five of these, 3 oligoden-
drogliomas, 2 glioblastoma multiforme, were from pedi-
atric patients. The three oligodendrogliomas did not
display any LOH. Within our adult patients with the his-
tological subtype of anaplastic oligodendrogliomas, the
prevalence of deletions was more common among
younger adults when compared to older adults (Table 4,
Figure 2). For anaplastic oligodendrogliomas, this differ-
ence was significant (Figure 2; p = 0.0319).
Feasibility and cost effectiveness
Not surprisingly, we found that the cost, per sample, of
performing this assay "in house" to be very cost effective
and economical ($450.00 US at the Health Sciences
Center vs $800.00 US per referral at Massachusetts Gen-
eral Hospital* for radioactive PCR analysis and $669.00
US at Mayo Medical Laboratories (MN) for fluorescent in
situ hybridization analysisa). We also found that data
obtained by using the radioactive PCR method easy to
interpret. In addition, the average time between receiving
a sample and obtaining the result was three days.
*Neurogenetics DNA diagnostic laboratory
http://www.mgh.harvard.edu/neuroDNAlab/
neuroDNA_chromosome.htm
apersonal communication. Website: http://
216.245.167.14:81/MALHTML/80029_btm.html
Discussion
Because of the biological diversity of gliomas, classifica-
tion by histology remains an uncertain science [2,11,12].
At present, there are a number of competing grading
systems, all of which are somewhat subjective and influ-
enced greatly by sampling adequacy. Consequently, histo-
logical appearance is only 80% accurate in predicting
tumor genotype in low-grade diffuse gliomas [13]. More-
over, it has been observed that tumor genotype rather
than histological appearance more closely predicts chem-
osensitivity [13]. Recently, through molecular analysis
strategies, it has been shown that oligodendrogliomas are
more likely to exhibit loss of chromosome 1p and 19q
and that these tumors respond favorably to PCV chemo-
therapy [5]. Although it is well known that chromosome
1p loss also occurs in other subtypes of high-grade glio-
mas, this has been shown to occur far less commonly in
oligodendrogliomas [7].
Oligodendrogliomas are reported to constitute about
11% of all primary gliomas (Central Brain Tumor Regis-
try, US 1992–1997). We observed a slightly higher fre-
quency of occurrence (31/161; 19%) in our study
population. In this study we also wanted to assess the
prevalence of 1p and 19q losses in anaplastic oligoden-
drogliomas and low-grade oligodendrogliomas and in a
small-centralized referral community such as Manitoba.
The high frequency of combined chromosome 1p and
19q loss in oligodendrogliomas and in glioblastomas,
compared to other gliomas analyzed in this study, was
similar to the findings of other reports. In one study [5]
22/34 of the oligodendrogliomas analysed displayed
combined chromosomes 1p and 19q losses. Another
study reported combined losses in 21/32 oligodendrogli-
omas [14]. In addition, in a study carried out at a larger
centre [15], it was found that 5/61 glioblastomas had
both 1p and 19q deletions and this subset of patients had
a better clinical outcome. In the present study, 2/21 gliob-
66 M 1 deletion 1 deletion 1 deletion 1 deletion glioblastoma multiforme 4
66 M non-informative 0 deletion non-informative 0 deletion glioblastoma multiforme 4
70 M 0 deletion 0 deletion 1 deletion 1 deletion glioblastoma multiforme 4
74 M 0 deletion 0 deletion 0 deletion 0 deletion glioblastoma multiforme 4
74 M non-informative 0 deletion non-informative non-informative glioblastoma multiforme 4
75 M 0 deletion 0 deletion 1 deletion 1 deletion glioblastoma multiforme 4
76 M 1 deletion non-informative 0 deletion 0 deletion glioblastoma multiforme 4
70 M 0 deletion 0 deletion 0 deletion 0 deletion dysembryoplastic neuroepithial 
tumor
1
73 F 0 deletion 0 deletion 0 deletion 0 deletion astrocytoma, anaplastic 3
* pediatric patients. # partial deletions on chromosome 1. + anaplastic with post radiation changes. Homozygous: Both parental alleles in the 
patient's normal constitutional DNA are identical and migrated as 1 apparent band on a polyacrylamide gel. Homozygous alleles were considered 
non-informative and not used in the analysis. 0 deletion: The parental alleles migrated as 2 separate bands (heterozygous alleles) and no LOH was 
detected in the tumor DNA. 1 deletion: The tumor DNA demonstrated a LOH at that locus.
Table 3: Summary of LOH data in 63 gliomas. (Continued)BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/6
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Representative deletion mapping Figure 1
Representative deletion mapping: LOH at 4 loci, D1S508, D1S2734, D19S219 and D19S412, in tumors from four differ-
ent patients (panels A, B, C, D). Comparison between the patient's constitutional DNA (N) and tumor DNA (T) reveals in 
panel A, a loss of allele 1 in the tumor DNA; in panel B, loss of allele 1; in panel C, loss of allele 2 and in panel D, loss of allele 
2. A faint band was sometimes observed in lanes with tumor DNA, most likely reflecting some minimal contamination with 
normal DNA. M = molecular weight marker; 1 = allele 1; 2 = allele 2.BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/6
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lastomas had both 1p and 19q deletions, which is very
comparable.
We observed that a LOH at the D1S2734 locus was always
accompanied by a LOH at the D1S508 locus. We also
observed that a loss of D1S2734 was always associated
with loss of 19q, which is consistent with other reports
[16]. In addition, it has been speculated that loss of 19q
may precede loss of chromosome 1 [7,17]. These associa-
tions suggest that a deletion at D1S2734 may be 100%
reliable in predicting LOH at D1S508 and deletion of 19q.
Thus, the identification of a LOH at the D1S2734 locus in
oligodendrogliomas may be sufficient to determine
chromosome1p and 19q deletions in these tumors.
Indeed our sample size being small, an alternate explana-
tion for the observed association between a loss of
D1S2734 locus and the D1S508 locus is that these loci
may be more polymorphic than the D19S219 and the
D19S412 loci. Further studies will need to be done to con-
firm this observation.
Partial deletions were identified at D1S508 in tumors
(one anaplastic oligoastrocytoma, and one glioblastoma
multiforme) from two patients, but none were found in
any of the oligodendrogliomas analyzed. This observation
is in agreement with a previous report that partial dele-
tions of chromosome 1p and 19q are more likely to occur
in astrocytomas and least likely to occur in oligodendrog-
liomas [17].
Most importantly, we observed that within the anaplastic
oligodendrogliomas category, older patients (60 years of
age and older) had significantly fewer chromosomal
losses of 1p and 19q than that of younger patients (18–59
Anaplastic oligodendrogliomas had significantly fewer deletions in younger adults (18–59 yr) than in older adults (60 yr and  over) Figure 2
Anaplastic oligodendrogliomas had significantly fewer deletions in younger adults (18–59 yr) than in older adults (60 yr and 
over).BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/6
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years of age). Moreover, the level of deletions observed in
oligodendrogliomas from younger adults was also higher
than the proportion seen in either glioblastoma multi-
form or other gliomas from the younger patients. The
observation that age may be a factor in the genetic altera-
tions of gliomas is not novel, as the failure to observe
many deletions in the pediatric tumors is not uncommon
[18]. However, our data suggests that this pattern of
genetic alteration in oligodendrogliomas may be unique
and the observation that a specific genetic age-based
difference exists in oligodendrogliomas, is novel. These
results could have implications for treatment modalities
that may be selected for patients 60 years of age and older
where these deletions are few compared to younger adult
patients. It remains to be seen whether our referral popu-
lation is different in this regard from other populations.
In addition to demonstrating feasibility, we examined
cost effectiveness of the procedure. Not surprisingly, we
found that the cost per patient sample was 50–75% lower
when this assay was performed "in house" at our center.
Being a small health care facility, we also wanted to com-
pare our turnaround with that of the larger centers. In our
laboratory the assay took as little as three days to perform,
which is a much shorter turnaround time than that (~2
weeks) of the larger referral laboratories, using radioactive
PCR methods.
Conclusions
The Winnipeg Health Sciences Centre is a small tertiary
center that receives patients from the province of Mani-
toba and part of Northwestern Ontario. The population is
very diverse and includes a large aboriginal community.
Further studies should reveal whether the age-related dif-
ferences that we observed in oligodendrogliomas occur in
all populations. In addition, this study highlights the abil-
ity of a small tertiary center to carry out this molecular
genetic assay to serve its own population efficiently and
cost effectively. By so doing, the test is now more readily
and more rapidly available to a larger number of patients.
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